Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Germany
  4. Xetra
  5. Evotec SE
  6. News
  7. Summary
    EVT   DE0005664809

EVOTEC SE

(EVT)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Evotec : Positive Phase IIb data for investigational P2X3 antagonist in patients with refractory chronic cough

08/04/2021 | 10:37am EST

Evotec SE (Frankfurt Stock Exchange, MDAX/TecDAX, ISIN: DE 000 566480 9, WKN 566480) announces that the Company has been informed by Bayer about positive Phase IIb results from a clinical trial evaluating the efficacy and safety of the investigational P2X3 receptor antagonist eliapixant (BAY1817080) in patients with refractory chronic cough.

The underlying molecule is a P2X3 receptor antagonist in Bayer's clinical development pipeline originating from a former Evotec/Bayer multi-target research alliance. The primary efficacy outcome was met showing a statistically significant improvement in 24-hour cough counts per hour (average hourly cough frequency based on 24-hour sound recordings) over placebo after 12 weeks of treatment. The data showed a favourable safety and tolerability profile.

Under the agreement from 2012, Evotec would be entitled to its next financial milestone payment upon start of a Phase III clinical study, to be decided by Bayer.

Contact:

Dr Werner Lanthaler

Chief Executive Officer

Evotec SE

Tel: +49(0)40.560 81-242

(C) 2021 Electronic News Publishing, source ENP Newswire

Stocks mentioned in the article
ChangeLast1st jan.
EVOTEC SE 0.69% 42.55 Delayed Quote.40.52%
GREENVOLT - ENERGIAS RENOVÁVEIS, S.A. -0.98% 6.04 Real-time Quote.0.00%
All news about EVOTEC SE
11/18EQRx and Evotec Announce Integrated Drug Discovery and Development Partnership
BU
11/18EVOTEC : and EQRx announce integrated drug discovery and development partnership
PU
11/18Evotec and EQRx announce integrated drug discovery and development partnership
EQ
11/18Evotec SE and EQRx Announce Integrated Drug Discovery and Development Partnership
CI
11/16EVOTEC : announces the exercise of the Greenshoe option
PU
11/12EVOTEC : Deutsche Bank reaffirms its Neutral rating
MD
11/12Evotec SE Reports Earnings Results for the Third Quarter and Nine Months Ended Septembe..
CI
11/11Evotec SE reports results for the first nine months 2021 and provides corporate update
PU
11/11Evotec SE reports results for the first nine months 2021 and provides corporate update
EQ
11/11Evotec Confirms FY21 Earnings Outlook, Midterm Targets
MT
More news
Analyst Recommendations on EVOTEC SE
More recommendations
Financials
Sales 2021 566 M 641 M 641 M
Net income 2021 54,2 M 61,3 M 61,3 M
Net cash 2021 303 M 343 M 343 M
P/E ratio 2021 129x
Yield 2021 -
Capitalization 7 453 M 8 434 M 8 435 M
EV / Sales 2021 12,6x
EV / Sales 2022 11,4x
Nbr of Employees 4 081
Free-Float 87,6%
Chart EVOTEC SE
Duration : Period :
Evotec SE Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends EVOTEC SE
Short TermMid-TermLong Term
TrendsNeutralNeutralBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 7
Last Close Price 42,55 €
Average target price 39,17 €
Spread / Average Target -7,94%
EPS Revisions
Managers and Directors
Werner Lanthaler Chief Executive Officer
Enno Spillner Chief Financial Officer
Iris L÷w-Friedrich Chairman-Supervisory Board
Cord E. Dohrmann Chief Scientific Officer
Craig L. Johnstone Chief Operating Officer
Sector and Competitors
1st jan.Capi. (M$)
EVOTEC SE40.52%8 434
MODERNA, INC.215.53%133 648
LONZA GROUP AG29.85%59 443
IQVIA HOLDINGS INC.46.26%50 064
SEAGEN INC.-3.22%30 994
CELLTRION, INC.-40.39%24 431